Nurix to present phase 1 data for BTK Degrader Bexobrutideg in CLL and Waldenström Macroglobulinemia at EHA 2025 and ICML

Nurix Therapeutics, Inc. announced that data from the Company’s ongoing Phase 1a/b clinical trial of bexobrutideg (NX-5948) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Waldenström macroglobulinemia will be presented at two major upcoming scientific conferences.

Data will be featured in two posters at the European Hematology Association 2025 Congress (EHA 2025), taking place June 12–15, 2025, in Milan, Italy, and in an oral presentation and poster at the 18th International Conference on Malignant Lymphoma (18-ICML), to be held June 17–21, 2025, in Lugano, Switzerland.

EHA 2025 Presentation Details:

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenting author: Zulfa Omer, M.D., Assistant Professor Internal Medicine, College of Medicine, University of Cincinnati, Cincinnati, OH, USA
Session title: Poster Session 1
Session date and time: Friday, June 13 (18:30 – 19:30 CEST)
Abstract ID: PF571

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: Dima El-Sharkawi, M.B., B.S., M.A., Ph.D., MRCP FRCPath, Consultant Haematologist, Royal Marsden NHS Foundation Trust, Sutton, UK
Session title: Poster Session 2
Session date and time: Saturday, June 14 (18:30 – 19:30 CEST)
Abstract ID: PS1883

18-ICML Oral Presentation Details:

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed refractory CLL: updated findings from an ongoing Phase 1a Study
Presenter: Alexey Danilov, M.D., Ph.D., Marianne and Gerhard Pinkus Professor in Early Clinical Therapeutics, Co-Director of Toni Stephenson Lymphoma Center, City of Hope National Medical Center, Duarte, CA, USA
Session title: 18: New Drugs
Session date and time: Saturday, June 21 (9:30 CEST).
Abstract ID: 093

18-ICML Poster Presentation Details:

Title: Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, shows high clinical activity and tolerable safety in an ongoing Phase 1a/b study in patients with Waldenström macroglobulinemia
Presenting author: David Lewis, M.D., Consultant Hematologist, Derriford Hospital; Associate Professor, Derriford Hospital, Plymouth, UK
Session title: Poster Session (Odd numbered posters)
Session date and time: Thursday, June 19 (10:00-18:00 CEST)
Abstract ID: 437